# BayFirst Financial Corp.: financial statements, quarterly

BAFN · Nasdaq · CIK 1649739 · [Financials](/sectors/financials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/bafn.md) · [Financials](/companies/bafn/financials.md) · [Filings](/companies/bafn/filings.md) · [Insiders](/companies/bafn/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/bafn/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Interest expense | $m | [9.2](/filings/0001649739-23-000323.md) | [10.0 d](/filings/0001649739-24-000122.md) | [10.4](/filings/0001649739-24-000138.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [0.7](/filings/0001649739-24-000286.md) | [0.7 d](/filings/0001649739-25-000106.md) | [0.3](/filings/0001649739-25-000129.md) | [0.3](/filings/0001649739-25-000238.md) | [0.4](/filings/0001649739-25-000250.md) | [2.5 d](/filings/0001649739-26-000049.md) | [(0.3)](/filings/0001649739-26-000050.md) | [(0.6)](/filings/0001649739-26-000061.md) | [(7.1)](/filings/0001649739-26-000049.md) | [(0.9) d](/filings/0001649739-26-000049.md) | [(2.0)](/filings/0001649739-26-000050.md) | [(11.4)](/filings/0001649739-26-000061.md) |
| Net income | $m | [1.9](/filings/0001649739-24-000286.md) | [1.7 d](/filings/0001649739-25-000106.md) | [0.8](/filings/0001649739-25-000129.md) | [0.9](/filings/0001649739-25-000238.md) | [1.1](/filings/0001649739-25-000250.md) | [7.4 d](/filings/0001649739-26-000049.md) | [(0.9)](/filings/0001649739-26-000050.md) | [(1.9)](/filings/0001649739-26-000061.md) | [(19.1)](/filings/0001649739-26-000049.md) | [(2.7) d](/filings/0001649739-26-000049.md) | [(5.9)](/filings/0001649739-26-000050.md) | [(32.7)](/filings/0001649739-26-000061.md) |
| Diluted EPS | $ per share | [0.41](/filings/0001649739-24-000286.md) | not reported | [0.11](/filings/0001649739-25-000129.md) | [0.12](/filings/0001649739-25-000238.md) | [0.18](/filings/0001649739-25-000250.md) | not reported | [(0.32)](/filings/0001649739-26-000050.md) | [(0.54)](/filings/0001649739-26-000061.md) | [(4.71)](/filings/0001649739-26-000049.md) | not reported | [(1.54)](/filings/0001649739-26-000050.md) | [(8.05)](/filings/0001649739-26-000061.md) |
| Basic EPS | $ per share | [0.42](/filings/0001649739-24-000286.md) | not reported | [0.11](/filings/0001649739-25-000129.md) | [0.12](/filings/0001649739-25-000238.md) | [0.18](/filings/0001649739-25-000250.md) | not reported | [(0.32)](/filings/0001649739-26-000050.md) | [(0.54)](/filings/0001649739-26-000061.md) | [(4.71)](/filings/0001649739-26-000049.md) | not reported | [(1.54)](/filings/0001649739-26-000050.md) | [(8.05)](/filings/0001649739-26-000061.md) |

- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [113](/filings/0001649739-23-000323.md) | [58.4](/filings/0001649739-25-000106.md) | [57.5](/filings/0001649739-24-000138.md) | [60.8](/filings/0001649739-24-000215.md) | [64.4](/filings/0001649739-24-000286.md) | [77.8](/filings/0001649739-26-000049.md) | [63.2](/filings/0001649739-25-000129.md) | [77.3](/filings/0001649739-25-000238.md) | [119](/filings/0001649739-25-000250.md) | [207](/filings/0001649739-26-000061.md) | [134](/filings/0001649739-26-000050.md) | [139](/filings/0001649739-26-000061.md) |
| Total assets | $m | [1,134](/filings/0001649739-23-000323.md) | [1,118](/filings/0001649739-25-000106.md) | [1,144](/filings/0001649739-24-000138.md) | [1,218](/filings/0001649739-24-000215.md) | [1,245](/filings/0001649739-24-000286.md) | [1,283](/filings/0001649739-26-000049.md) | [1,286](/filings/0001649739-26-000049.md) | [1,337](/filings/0001649739-26-000049.md) | [1,340](/filings/0001649739-26-000049.md) | [1,294](/filings/0001649739-26-000061.md) | [1,190](/filings/0001649739-26-000050.md) | [1,135](/filings/0001649739-26-000061.md) |
| Total liabilities | $m | [1,040](/filings/0001649739-23-000323.md) | [1,017](/filings/0001649739-25-000106.md) | [1,044](/filings/0001649739-24-000138.md) | [1,117](/filings/0001649739-24-000215.md) | [1,143](/filings/0001649739-24-000286.md) | [1,176](/filings/0001649739-26-000049.md) | [1,181](/filings/0001649739-26-000049.md) | [1,235](/filings/0001649739-26-000049.md) | [1,256](/filings/0001649739-25-000250.md) | [1,213](/filings/0001649739-26-000061.md) | [1,114](/filings/0001649739-26-000050.md) | [1,019](/filings/0001649739-26-000061.md) |
| Shareholders' equity | $m | [94.2](/filings/0001649739-24-000286.md) | [98.8](/filings/0001649739-26-000049.md) | [101](/filings/0001649739-25-000238.md) | [101](/filings/0001649739-25-000250.md) | [102](/filings/0001649739-25-000250.md) | [107](/filings/0001649739-26-000061.md) | [105](/filings/0001649739-26-000061.md) | [103](/filings/0001649739-26-000061.md) | [84.0](/filings/0001649739-26-000049.md) | [81.6](/filings/0001649739-26-000061.md) | [75.6](/filings/0001649739-26-000061.md) | [116](/filings/0001649739-26-000061.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Total assets: us-gaap:Assets
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [135 d](/filings/0001649739-24-000286.md) | [127 d](/filings/0001649739-25-000106.md) | [124](/filings/0001649739-25-000129.md) | [78.8 d](/filings/0001649739-25-000238.md) | [90.8 d](/filings/0001649739-25-000250.md) | [100 d](/filings/0001649739-26-000049.md) | [75.1](/filings/0001649739-26-000049.md) | [64.2 d](/filings/0001649739-26-000061.md) | [48.2 d](/filings/0001649739-26-000049.md) | [101 d](/filings/0001649739-26-000049.md) | [(3.2)](/filings/0001649739-26-000028.md) | [0.4 d](/filings/0001649739-26-000061.md) |
| Capital expenditure | $m | [0.5 d](/filings/0001649739-24-000286.md) | [1.4 d](/filings/0001649739-25-000106.md) | [1.0](/filings/0001649739-25-000129.md) | [0.4 d](/filings/0001649739-25-000238.md) | [0.3 d](/filings/0001649739-25-000250.md) | [(0.0) d](/filings/0001649739-26-000049.md) | [0.1](/filings/0001649739-26-000050.md) | [0.2 d](/filings/0001649739-26-000061.md) | [0.0 d](/filings/0001649739-25-000250.md) | [0.0 d](/filings/0001649739-26-000049.md) | [0.0](/filings/0001649739-26-000050.md) | [0.1 d](/filings/0001649739-26-000061.md) |
| Dividends paid | $m | [0.3 d](/filings/0001649739-24-000286.md) | [0.3 d](/filings/0001649739-25-000106.md) | [0.3](/filings/0001649739-25-000129.md) | [0.3 d](/filings/0001649739-25-000238.md) | [0.3 d](/filings/0001649739-25-000250.md) | [0.3 d](/filings/0001649739-26-000049.md) | [0.3](/filings/0001649739-26-000050.md) | [0.3 d](/filings/0001649739-26-000061.md) | [0.0 d](/filings/0001649739-25-000250.md) | [0.0 d](/filings/0001649739-26-000049.md) | [0.0](/filings/0001649739-26-000050.md) | [0.0 d](/filings/0001649739-26-000061.md) |
| Share repurchases | $m | [0.0 d](/filings/0001649739-24-000286.md) | [0.0 d](/filings/0001649739-25-000106.md) | [0.0](/filings/0001649739-25-000129.md) | [0.0 d](/filings/0001649739-25-000238.md) | [0.0 d](/filings/0001649739-25-000250.md) | [0.0 d](/filings/0001649739-26-000049.md) | [0.3](/filings/0001649739-26-000050.md) | [0.0 d](/filings/0001649739-26-000061.md) | [0.0 d](/filings/0001649739-25-000250.md) | [0.0 d](/filings/0001649739-26-000049.md) | [0.0](/filings/0001649739-26-000050.md) | [0.0 d](/filings/0001649739-26-000061.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: us-gaap:PaymentsOfDividendsCommonStock
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | thousands of shares | [4,341](/filings/0001649739-23-000323.md) | [4,081](/filings/0001649739-24-000138.md) | [4,266](/filings/0001649739-24-000215.md) | [4,356](/filings/0001649739-24-000286.md) | [4,130](/filings/0001649739-25-000129.md) | [4,135](/filings/0001649739-25-000238.md) | [4,134](/filings/0001649739-25-000250.md) | [4,141](/filings/0001649739-26-000050.md) | [4,132](/filings/0001649739-26-000061.md) | [4,135](/filings/0001649739-25-000250.md) | [4,108](/filings/0001649739-26-000050.md) | [4,108](/filings/0001649739-26-000061.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 26,962,815 at 2026-08-05, from the cover of the [10-Q filed 2026-08-14](/filings/0001649739-26-000061.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:45 ET. No prices; not investment advice.